| Similar Articles |
|---|
 |
Managed Care
March 2005
Martin Sipkoff |
Direct-to-Consumer Ads Garner Mixed Outcomes DTC advertising's reputation as a bully may be largely overstated. There's little evidence that sales of specific drugs increase, and there may be some benefit.   |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
Pharmaceutical Executive
September 1, 2006
Beth Herskovits |
Freedom of Information IMS and Verispan sue New Hampshire to buy prescriber data and to protect the data sellers' free-speech rights. |
The Motley Fool
September 2, 2010
Brian Orelli |
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases. |
Nutra Solutions
June 1, 2005 |
Hidden Drug Costs Up to five salespeople from the same company may call on the same doctor about the same product. Drug makers spend over $7 billion on such calls each year, compared to $4 billion on direct-to-consumer advertising. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
Pharmaceutical Executive
January 1, 2007 |
Direct to Consumer: When Television Isn't Enough Pharmaceutical marketers are tightening mass-marketing budgets and putting cash into direct media and integrated programs. |
Managed Care
February 2007
MargaretAnn Cross |
How Much Trouble Does Health Care Marketing Cause? Whether for drugs, imaging, surgery, or emergency services, direct-to-consumer advertising sparks lively debate. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
The Motley Fool
December 10, 2010
Brian Orelli |
Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered. |
The Motley Fool
May 23, 2007
Brian Orelli |
Pharma TV -- All Drugs, All the Time A combined media effort of four big pharmas in Europe sounds like a great idea, from an investor's perspective. But will it work? |
The Motley Fool
September 2, 2008
Brian Orelli |
Lipitor Is Back on the Tube Direct-to-consumer ads have to walk a line. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
January 31, 2011
Brian Orelli |
Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
Pharmaceutical Executive
June 1, 2007
Stan Bernard |
Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control. |
Pharmaceutical Executive
April 1, 2006
Diane West |
Media Spend Trends: Change the Channel Drug marketers still spend lots of money. But they aim at PhRMA loopholes. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
Pharmaceutical Executive
June 1, 2006
Philip A. George |
Alternative Media: Online Med Sites Gain Patient Trust Pharma could benefit from a little less TV. |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
Pharmaceutical Executive
June 1, 2005
Boschwitz et al. |
Track Patients, Not Prescriptions Why pharma companies reject anonymous patient-level data, and why they can't do without it for long. |
The Motley Fool
February 2, 2011
Brian Orelli |
Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks. |
Pharmaceutical Executive
May 1, 2007
Diane West |
Spend Trends 2007: Hang 10 Direct-to-Consumer Advertising Hits Its First Decade: Dr. Dot-Com... Digital Detailing... etc. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
May 18, 2009
Brian Orelli |
Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship. |
BusinessWeek
November 4, 2009
Arlene Weintraub |
Ask Your Doctor If This Ad Is Right for You The drug industry is spending billions on TV ads, but they may be scaring consumers away |
Pharmaceutical Executive
July 30, 2007 |
Direct to Consumer: Creativity Through Understanding Creative consumer campaigns begin with a clear understanding of pharma rules and regulations. |
Pharmaceutical Executive
May 1, 2009 |
Ad(Ventures) in Pharmaland Despite the downside in ad spend, an upside remains in the digital space that's wide open for exploration. |
Pharmaceutical Executive
March 1, 2007
Jeffrey Zornitsky |
Sales Management: Get Committed By better managing relationships with physicians, pharma companies can develop a base of dedicated prescribers. |
The Motley Fool
October 18, 2010
Brian Orelli |
Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs. |
Pharmaceutical Executive
September 1, 2006
Patrick Clinton |
From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs. |
Pharmaceutical Executive
August 1, 2006
Patrick Clinton |
From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible. |
Pharmaceutical Executive
February 1, 2006
Chandler & Chicco |
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways |
Pharmaceutical Executive
May 1, 2012 |
The Personal Touch in Digital Promotion The shift from sales rep meetings to digital selling methods must include innovation and a physician-centered mindset in order to be successful. |
Chemistry World
April 6, 2011
Andrew Turley |
Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'. |
Pharmaceutical Executive
August 1, 2006 |
Introduction: Pharm Exec at 25 A pharmaceuticals magazine celebrates its 25th anniversary. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
Pharmaceutical Executive
January 1, 2007
Jeffrey Zornitsky |
Sales Management: Get Committed By better managing relationships with physicians, pharma companies can develop a base of dedicated prescribers. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
The Motley Fool
February 9, 2010
Brian Orelli |
Pfizer's Slippery Slope Discount cards for drugs help Pfizer track patients' use. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
June 8, 2011
Brian Orelli |
Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming. |
Reason
Aug/Sep 2001
Jacob Sullum |
Through the Nose An FDA advisory committee has voted overwhelmingly to recommend over-the-counter status for Claritin, Allegra, and Zyrtec, three popular prescription allergy drugs. But the drugs' manufacturers are opposing a switch, fearing that it could hurt their profits... |
The Motley Fool
September 3, 2010
Brian Orelli |
Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years |
